Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?

Journal of the Pancreas

Volumn 8, Issue 3, 2007, Pages 279-288

  Kim, Richard ^a   Saif, Muhammad Wasif ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Capecitabine; Dihydrouracil dehydrogenase (NADP); Fluorouracil; Pancreatic neoplasms; Radiotherapy; Thymidine phosphorylase

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; STREPTOZOCIN; TIPIFARNIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OXONIC ACID; S 1 (COMBINATION); TEGAFUR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DUODENAL ULCER BLEEDING; DUODENUM ULCER; EXTERNAL BEAM RADIOTHERAPY; GASTRIC ULCER BLEEDING; HUMAN; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; STOMACH ULCER; SURVIVAL TIME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VOMITING; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; MORTALITY; PANCREAS TUMOR; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG COMBINATIONS; FLUOROURACIL; HUMANS; NEOADJUVANT THERAPY; OXONIC ACID; PACLITAXEL; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TEGAFUR;

EID: 34249714697     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106-30. [PMID 16514137]
2. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg 1995; 221:133-48. [PMID 7531966]
3. Bold RJ, Charnsangavej C, Cleary KR, Jennings M, Madray A, Leach SD, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999; 3:233-43. [PMID 10481116]
4. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47:5-27. [PMID 8996076]
5. Yeo CJ, Cameron JL. Pancreatic cancer. Curr Probl Surg 1999; 36:59-152. [PMID 10021685]
6. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567-79. [PMID 11307091]
7. Nakao A, Takeda S, Sakai M, Kaneko T, Inoue S, Sugimoto H, Kanazumi N. Extended radical resection versus standard resection for pancreatic cancer: The rationale for extended radical resection. Pancreas 2004; 28:289-92. [PMID 15084973]
8. Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience. Am Surg 2000; 66:378-85. [PMID 10776876]
9. Moertel CG, Childs DS Jr, Reitemeier RJ, Colby MY Jr, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2:865-7. [PMID 4186452]
10. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705-10. [PMID 7284971]
11. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005; 62:1345-50. [PMID 16029791]
12. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer 1985; 56:2563-8. [PMID 2864997]
13. Whittington R, Neuberg D, Tester WJ, Benson AB 3rd, Haller DG. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. J Clin Oncol 1995; 13:227-32. [PMID 7799024]
14. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997; 79:1516-20. [PMID 9118032]
15. Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005; 23:8679-87. [PMID 16314628)
16. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548-57. [PMID 8862723]
17. Ikeda M, Okusaka T, Ito Y, Ueno H, Morizarte C, Furuse J, et al. A phase I trial of S-1 with concurrent radiotherapy in locally advanced pancreatic cancer. Proc GI Am Soc Clin Oncol 2007; (Abstract 144).
18. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [PMID 9196156]
19. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001; 7:2246-53. [PMID 11489798]
20. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17:2208-12. [PMID 10561277]
21. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003; 34:107-16. [PMID 15361643]
22. Moore AM, Cardenes H, Johnson CS, Helft P, Seitz D, Stephens A, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: A hoosier oncology group trial. ASCO Annual Meeting 2004; 22:(Abstract 4105).
23. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002; 81:138-43. [PMID 12407726]
24. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001; 19:4202-8. [PMID 11709563]
25. King TC, Estalilla OC, Safran H. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin Radiat Oncol 1999; 9:4-11. [PMID 10210535]
26. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001; 49:1275-9. [PMID 11286834]
27. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004; 27:51-6. [PMID 14758134]
28. Martenson JA, Vigliotti AP, Pitot HC, Geeraerts LH, Sargent DJ, Haddock MG, et al. A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003; 55:1305-10. [PMID 12654442]
29. Haddock MG, Swaminathan R, Alberts SR, Hauge MD, Foster NR, Martenson JA, et al. Gemcitabine (gem), cisplatin (cis) and radiation therapy (rt) for patients with locally advanced pancreatic adenocarcinoma (aca): A north central cancer treatment group (NCCTG) phase ii study. ASCO Annual Meeting 2004; 22:(Abstract 4121).
30. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB 3rd. Eastern cooperative oncology group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 2000; 18:3384-9. [PMID 11013279]
31. Fogelman DR, Schreibman S, Sherman W, Siegel AB, Ennis R, Wong T, et al. Neoadjuvant GTX and radiation for unresectable pancreatic cancer: A prospective phase II trial. Proc GI Am Soc Clin Oncol 2007; (Abstract 143).
32. Leung RC, Ryan T, Newman E, Chandra A, Hochster H. A phase I/II study of induction oxaliplatin, 5FU chemoradiation in patients with locally advanced, unresectable pancreatic cancer. Proc GI Am Soc Clin Oncol 2007; (Abstract 157).
33. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Annual Meeting 2005; 23:(Abstract 1).
34. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430-8. [PMID 15084616]
35. Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22:3776-83. [PMID 15365074]
36. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3:373-8. [PMID 3973648]
37. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988; 80:751-5. [PMID 2898536]
38. Chauffert B, Mornex F, Bonnetain F, Triboulet JP, Bouche O, Rougier P, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. ASCO Annual Meeting 2006; 24:(Abstract 4008).
39. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16. [PMID 15908661]
40. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002; 87:161-7. [PMID 12107836]